Literature DB >> 31835765

Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value.

George Markousis-Mavrogenis1, Vasiliki-Kalliopi Bournia2, Stylianos Panopoulos2, Loukia Koutsogeorgopoulou3, George Kanoupakis4, Dimitrios Apostolou4, Gikas Katsifis5, Michail Polychroniadis6, Theodoros Dimitroulas7, Genovefa Kolovou1, George D Kitas8, Sophie I Mavrogeni1, Petros P Sfikakis2.   

Abstract

BACKGROUND: Acute cardiac events are a significant contributor to mortality in systemic sclerosis (SSc). However, echocardiographic evaluation may be deceptively normal during an acute presentation. We hypothesized that in diffuse SSc patients presenting with acute cardiac events and a normal echocardiogram, cardiovascular magnetic resonance (CMR) would have incremental diagnostic/prognostic value.
METHODS: 50 consecutive diffuse SSc patients with normal echocardiograms were evaluated using a 1.5T system. A total of 27 (63%) had experienced an acute cardiac event three to tendays before CMR evaluation (rhythm disturbances, angina pectoris, shortness of breath). Left/right ventricular (LV/RV) volumes and ejection fractions (EF), as well as LV mass, the T2-signal ratio, early/late gadolinium enhancement (EGE/LGE), native/post-contrast T1-mapping, T2-mapping and extracellular volume fraction (ECV) were compared between the event and no-event groups.
RESULTS: No differences were identified in LV/RV volumes/EF/mass. In logistic regression analyses, independent predictors of belonging to the event group were EGE (odds ratio (95% CI): 1.55 (1.06-2.26), p = 0.024), LGE (1.81 (1.23-2.67), p = 0.003), T2 mapping (1.20 (1.06-1.36), p = 0.004) and native/post-contrast T1 mapping (1.17 (1.04-1.32), p = 0.007 and 0.86 (0.75-0.98), p = 0.025). At a median follow-up of ~1.2 years, 42% vs. 11% of the event/no-event group respectively reached a combined endpoint of event occurrence/recurrence or cardiovascular mortality. Of the independent predictors resulting from logistic regression analyses, only LGE (hazard ratio (95% CI): 1.20 (1.11-1.30), p < 0.001), T2-mapping (1.07 (1.01-1.14), p = 0.025) and native T1-mapping (1.08 (1.01-1.15), p = 0.017) independently predicted the combined endpoint.
CONCLUSIONS: A normal echocardiogram does not preclude myocardial lesions in diffuse SSc patients, which can be detected by CMR especially in symptomatic patients.

Entities:  

Keywords:  adverse events; cardiovasular magnetic resonance; diffuse subenocardial fibrosis; echocardiography; myocarditis; systemic sclerosis

Year:  2019        PMID: 31835765     DOI: 10.3390/diagnostics9040220

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  9 in total

Review 1.  T2 mapping in myocardial disease: a comprehensive review.

Authors:  Aaron T O'Brien; Katarzyna E Gil; Juliet Varghese; Orlando P Simonetti; Karolina M Zareba
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-06       Impact factor: 6.903

2.  Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis.

Authors:  Selina J Hein; Maximilian Knoll; Fabian Aus dem Siepen; Jennifer Furkel; Stefan Schoenland; Ute Hegenbart; Hugo A Katus; Arnt V Kristen; Mathias Konstandin
Journal:  World J Cardiol       Date:  2021-03-26

Review 3.  Cardiovascular Magnetic Resonance Reveals Cardiac Pathophysiology in Autoimmune Rheumatic Diseases.

Authors:  George Markousis-Mavrogenis; Petros P Sfikakis; Loukia Koutsogeorgopoulou; Theodoros Dimitroulas; Gikas Katsifis; Aikaterini Giannakopoulou; Paraskevi Voulgari; Genovefa Kolovou; George D Kitas; Sophie I Mavrogeni
Journal:  Mediterr J Rheumatol       Date:  2021-03-31

4.  CHLD score, a new score based on traditional risk factor evaluation and long-term cardiovascular outcomes in patients with systemic sclerosis.

Authors:  Klaudia Gieszczyk-Strózik; Maciej T Wybraniec; Małgorzata Widuchowska; Ligia Brzezińska-Wcisło; Przemysław Kotyla; Eugeniusz Kucharz; Katarzyna Mizia-Stec
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

5.  The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis.

Authors:  Jacqueline L Vos; Steele C Butcher; Federico Fortuni; Xavier Galloo; Laura Rodwell; Madelon C Vonk; Jeroen J Bax; Sander I van Leuven; Jeska K de Vries-Bouwstra; Miranda Snoeren; Saloua El Messaoudi; Nina A Marsan; Robin Nijveldt
Journal:  Front Cardiovasc Med       Date:  2022-03-17

Review 6.  Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management.

Authors:  Peter Glynn; Sarah Hale; Tasmeen Hussain; Benjamin H Freed
Journal:  Front Cardiovasc Med       Date:  2022-03-31

Review 7.  The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.

Authors:  Ioana Bratoiu; Alexandra Maria Burlui; Anca Cardoneanu; Luana Andreea Macovei; Patricia Richter; Gabriela Rusu-Zota; Ciprian Rezus; Minerva Codruta Badescu; Andreea Szalontay; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

8.  Ventricular Tachycardia Has Mainly Non-Ischaemic Substrates in Patients with Autoimmune Rheumatic Diseases and a Preserved Ejection Fraction.

Authors:  George Markousis-Mavrogenis; George Poulos; Theodoros Dimitroulas; Aikaterini Giannakopoulou; Clio Mavragani; Vasiliki Vartela; Dionysia Manolopoulou; Genovefa Kolovou; Paraskevi Voulgari; Petros P Sfikakis; George D Kitas; Sophie I Mavrogeni
Journal:  Diagnostics (Basel)       Date:  2021-03-15

9.  Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases.

Authors:  Tobias Hoffmann; Peter Oelzner; Martin Busch; Marcus Franz; Ulf Teichgräber; Claus Kroegel; Paul Christian Schulze; Gunter Wolf; Alexander Pfeil
Journal:  Diagnostics (Basel)       Date:  2021-12-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.